• Clinical Care OptionsNew for GAPNA members: Clinical Care Options

    GAPNA has partnered with a Clinical Care Options to offer an ongoing series of free CNE programs available to GAPNA members. "Vaccinations and Healthy Aging: Protecting Your Older Patients From Shingles" is the latest program offered.

    In this live webinar, expert faculty expert faculty discuss how important it is to prevent shingles in older patients.

    Find out about it!

  • CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources

     

  • GAPNA 2020 National President Deborah Dunn, EdD, MSN, GNP-BC, ACNS-BC, GS-C interviews Dr. Ron Billano Ordona, DNP, FNP-BC about providing home-based primary care during COVID 19.

    "Facing Forward: Providing Home-based Primary Care during COVID 19"


    View the Video

Lonhala Magnair

Combination Chemotherapy Increases the Risk for Adverse Events in Elderly Patients with Colorectal Cancer

About 70% of colorectal cancers (CRC) develop in patients over the age of 65.

Treatment options in these elderly patients include the use of single-agent or combination-based chemotherapies. However, elderly patients are particularly vulnerable to side effects, especially when drugs are used in combination, according to researchers.

Medicare data were used to determine what types of chemotherapy, if any, these patients received. Patients who received chemotherapy tended to be younger, had more advanced cancers, and were more likely to be married compared to patients who did not get chemotherapy.

All patients, whether receiving chemotherapy or not, had a high incidence of symptoms and laboratory test abnormalities, which increased after patients began receiving chemotherapy. Compared to patients on fluorouracil alone, those on an oxaliplatin-based regimen had higher rates of adverse events, including nausea and neuropathy.

Those 70 years of age and older were more likely to experience certain adverse events such as infection, anemia, delirium, and heart disease.

For details, see Cen et al. (2012). Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Annals of Oncology, 23(6), 1503-1511. doi:10.1093/annonc/mdr449

Related Topic 1: 

GAPNA Newsletter Issue: 

VIEW ALL ARTICLES: